The global cannabis industry stands on the cusp of explosive growth, primed to unlock billions in untapped potential. Reclassifying cannabinoids from Schedule I compounds could be the key catalyst, paving the way for substantial investment and research. This monumental shift would usher in a wave of innovation, with health-focused companies leverag